PureTech Health plc (OTCMKTS:PTCHF – Get Free Report)’s stock price was down 0.9% during mid-day trading on Wednesday . The company traded as low as $2.23 and last traded at $2.26. Approximately 3,159 shares traded hands during trading, a decline of 91% from the average daily volume of 36,329 shares. The stock had previously closed at $2.28.
PureTech Health Stock Performance
The firm has a 50-day simple moving average of $2.71 and a 200 day simple moving average of $2.58.
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Featured Stories
- Five stocks we like better than PureTech Health
- Stock Dividend Cuts Happen Are You Ready?
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- What is a buyback in stocks? A comprehensive guide for investors
- Qualcomm Stock Continues to Rise in the Face of Negative News
- Most active stocks: Dollar volume vs share volume
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
